Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform☆

@inproceedings{Denning2016CardiomyocytesFH,
  title={Cardiomyocytes from human pluripotent stem cells: From laboratory
curiosity to industrial biomedical platform☆},
  author={Chris N. Denning and Viola Borgdorff and James Crutchley and Karl S.A. Firth and Vinoj T. George and Spandan Kalra and Alexander Kondrashov and Minh Duc Hoang and Diogo Mosqueira and Asha K Patel and Ljupcho Prodanov and Divya Rajamohan and William C. Skarnes and James G. W. Smith and Lorraine E. Young},
  booktitle={Biochimica et biophysica acta},
  year={2016}
}
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differentiation have improved patient care, progressed drugs to clinic and opened a new era in safety pharmacology. Nevertheless, predictive cardiotoxicity using hPSC-CMs contrasts from failure to almost total… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS